An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy

An orally administered BY-2 plant cell-expressed recombinant anti-TNF fusion protein (PRX-106) consists of the soluble form of the human TNF receptor (TNFR) fused to the Fc component of a human IgG1 domain. Aim This study aim at determining the safety and the immune modulatory effect of an oral admi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of immunological methods 2017-07, Vol.446, p.21-29
Hauptverfasser:	Almon, Einat, Khoury, Tawfik, Drori, Ariel, Gingis-Velitski, Svetlana, Alon, Sari, Chertkoff, Raul, Mushkat, Mordechai, Shaaltiel, Yoseph, Ilan, Yaron
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Adult Anti-TNF fusion protein Cytokines - blood Etanercept - administration & dosage Etanercept - adverse effects Etanercept - blood Etanercept - immunology Humans Immunomodulation Immunotherapy Inflammatory Bowel Diseases - immunology Lymphocyte Activation Male Middle Aged Oral tolerance T-Lymphocytes, Regulatory - immunology T-Lymphocytes, Regulatory - physiology Tumor Necrosis Factor-alpha - immunology Tumor Necrosis Factor-alpha - metabolism Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!